Skip to main content

Every lot tested to a published numeric specification · Certificates hosted by the testing laboratory

Cart

Research Library Blends · View in catalog →

Modified GRF (1-29) / CJC-1295 No DAC + Ipamorelin - Prometheus / FIT-style

1 Identity

Fixed-ratio two-component article: two synthetic C-terminally amidated peptides, co-lyophilized. Not a molecule and not a single substance; a formulation. Both components carry non-proteinogenic or D-configured positions, so the whole article is P3 and a chiral method is mandatory rather than optional.

Sequence
Per component; each component's full identity lives on its own record and is cross-referenced rather than restated. Component A, Modified GRF (1-29): Y-(D-A)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2, 29 residues, C-terminus A primary carboxamide and not a free acid, four substitutions against native human GHRH(1-29) - D-Ala2, Gln8, Ala15, Leu27. The Leu27 substitution removes the only sulfur atom in the native sequence, which is the single most useful compositional handle on the article: any sulfur in an elemental result or isotope pattern indicates sermorelin-family contamination. Component B, Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2, five residues of which three are outside the proteinogenic set - 2-aminoisobutyric acid at position 1, achiral; D-3-(2-naphthyl)alanine at 3; D-phenylalanine at 4. Neither component contains cysteine, methionine, sulfur or a disulfide.
Molecular formula
Per component, never as a sum. Modified GRF (1-29) C152H252N44O42 (C-terminal amide, the specified article); ipamorelin C38H49N9O5 (free base). No combined formula is written, because a mixture has no molecular formula and a certificate printing one describes something that does not exist. Salt is stated per component - net peptide content on a trifluoroacetate lot of the 29-mer typically runs 75-85 percent, and ipamorelin's bis-trifluoroacetate at 939.91 is 24.3 percent counterion by weight.
Average mass
Per component: Modified GRF (1-29) 3,367.954 Da; ipamorelin 711.868 Da, both on IUPAC 2021 abridged conventional atomic weights. Worked example at 10 + 10 mg, 20 mg total nominal fill: 2.969 against 14.048 micromol - a 1.00-to-4.73 molar ratio out of a 1.0-to-1.0 mass ratio. Named comparators that must be excluded rather than assumed away: CJC-1295 with DAC at 3,647.250, plus 279.30 Da; sermorelin at 3,357.93, minus 10.02 Da and containing one sulfur; the des-amido free acid of either component at plus 0.98 Da. Lots are checked against the monoisotopic figure rather than against the average, which on a 3.4 kDa peptide moves up to 0.05 Da between atomic-weight tables.
Monoisotopic mass
Per component. Modified GRF (1-29) 3,365.89358 Da neutral, observed multiply charged - [M+3H]3+ 1,122.97180, [M+4H]4+ 842.48067 - and reported as a deconvoluted neutral with the raw envelope shown. Ipamorelin 711.3857 neutral, [M+H]+ 712.3930, against a plus or minus 10 ppm identity window of plus or minus 0.0071 Da. Comparators: des-amido 29-mer 3,366.87759 (+0.98401); sermorelin 3,355.81870; CJC-1295 with DAC 3,645.01548. Identity is confirmed against both expected neutrals in one run.
Salt / variant note
(1) the name fork, which is the whole commercial problem with this article: 'CJC-1295 no DAC' at 3,367.954 against CJC-1295 (DAC:GRF) at 3,647.250, plus 279.30 Da and a thiol-reactive maleimide. A supplier who ships the conjugate against a 'no DAC' order has shipped a different molecule with a different stability profile. (2) sermorelin at 3,357.93, minus 10.02 Da, containing the sulfur the Leu27 substitution removed. (3) des-amido free acid of either component at plus 0.98 Da, requiring a high-resolution instrument to see. (4) ipamorelin salt: mono- through bis-trifluoroacetate. (5) ratio: 2+2 mg and 5+5 mg dose-shaped presentations circulate; no standard exists.

2 Class & testing panel

Form
Fixed-ratio blend
Testing panel
P3panel definitionfor both components, run per component rather than once on the mixture. Chiral amino acid analysis must report D-Ala2 on the 29-mer and D-2-Nal3 and D-Phe4 on the pentapeptide, and MS/MS must show the achiral non-proteinogenic Aib1, which carries no chiral limit and is therefore invisible to a chiral method. Each component is released against its full single-article P3 specification on the INPUT material before blending

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component, is graded on that component's record and is cross-referenced from here rather than restated. Ipamorelin's originator composition work dates from the mid-1990s. The Modified GRF (1-29) file is the GHRH-analogue literature, complicated throughout by the naming problem recorded above, since a large share of material studied or sold under one name is the other molecule.

4 Storage & specification

Storage
White to off-white co-lyophilized solid in a screw-cap amber borosilicate vial with a PTFE-lined closure, desiccant sachet in the secondary pack - a laboratory-chemical presentation, non-sterile, no sterility claim, no stoppered-and-crimped injection format. Store at -20 degrees C plus or minus 5 degrees C, tightly closed, desiccated, protected from light. Neither component contains cysteine, methionine or a disulfide, so inert headspace is not required here and its absence from the specification is a considered position rather than an omission. Sealed vials are equilibrated to ambient before opening. Reconstituted solution is aliquoted single-use at -80 degrees C.
Shelf life
Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and light-protected, from QA release - both component intervals being 24 months - and provisional pending this company's own data. Stability protocol: 0, 3, 6, 9, 12, 18 and 24 months at the labeled condition with a 6-month accelerated arm at 25 degrees C and 60 percent relative humidity, plus an ICH Q1B photostability arm run once on the launch lot. Iso-aspartate on the 29-mer is the attribute expected to limit the retest interval and is measured at every timepoint alongside the des-amido free acid of both components; gross purity is not expected to be the limiting number and a study trending only gross purity would miss both. Blend-specific attributes: per-component net content, the measured ratio, water and counterion per component.

This record reports identity, specification and study design. It does not state what the article does in a human body. Supplied under the caution: “CAUTION: Contains a new drug for investigational use only in laboratory research animals or for tests in vitro. Not for use in humans.